Eton Pharmaceuticals, Inc. - ETON EV/Sales Multiple

Public company logo of etonpharma.com (ETON)

Efficient delivery of orphan drugs provides Eton Pharmaceuticals (ETON) with high margins, although pressure from biotech startups and insurance risks creates uncertainty. The company's price-to-sales multiple helps identify consolidation zones, where the current metric equals 12324.26. Business stability is further supported by contract filling capacities for liquid forms operating without downtime.

Eton Pharmaceuticals - ETON Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

etonpharma.com - analytical breakdowns and key metrics (ETON)

- money and cash flow information:
Fundamental valuation:etonpharma.com (ETON)
Mass-produced product of Eton Pharmaceuticals

This ratio determines the market value of the business, accounting for net debt per unit of generated revenue. By analyzing the EV to revenue trend, an investor assesses the premium paid for an asset regardless of its financial leverage. The metric reveals an imbalance between capitalization and actual sales. For Eton Pharmaceuticals (ETON), this indicator reflects market confidence in the commercialization of its orphan drug portfolio. Pipeline diversification mitigates risks, stabilizing the company's valuation.